No abstract available
Plain language summary
This post hoc analysis of PIONEER I and II randomized clinical trials assesses whether receiving adalimumab is associated with decreased hematologic abnormalities and increased clinical improvement in patients with hidradenitis suppurativa.
MeSH terms
-
Adalimumab* / administration & dosage
-
Adalimumab* / adverse effects
-
Adalimumab* / therapeutic use
-
Adult
-
Anti-Inflammatory Agents / administration & dosage
-
Anti-Inflammatory Agents / adverse effects
-
Anti-Inflammatory Agents / therapeutic use
-
Female
-
Hematologic Diseases
-
Hidradenitis Suppurativa* / drug therapy
-
Humans
-
Male
-
Middle Aged
Substances
-
Adalimumab
-
Anti-Inflammatory Agents